Oakland, CA — Adolescents who use cannabis could face a significantly higher risk of developing serious psychiatric disorders by young adulthood, according to a large new study published today in JAMA Health Forum . The longitudinal study followed 463,396 adolescents ages 13 to 17 through age 26 and found that past-year cannabis use during adolescence was associated with a significantly higher risk of incident psychotic (doubled), bipolar (doubled), depressive and anxiety disorders. The study was conducted by researchers from Kaiser Permanente, the Public Health Institute’s Getting it Right from the Start, the University of California, San Francisco and the University of Southern California, and was funded by a grant from NIH’s National Institute on Drug Abuse (R01DA0531920).
The study analyzed electronic health record data from routine pediatric visits between 2016 and 2023. Cannabis use preceded psychiatric diagnoses by an average of 1.7 to 2.3 years. The study’s longitudinal design strengthens evidence that adolescent cannabis exposure is a potential risk factor for developing mental illness.
“As cannabis becomes more potent and aggressively marketed, this study indicates that adolescent cannabis use is associated with double the risk of incident psychotic and bipolar disorders, two of the most serious mental health conditions,” said Lynn Silver, M.D., program director of the Getting it Right from the Start, a program of the Public Health Institute, and a study co-author. “The evidence increasingly points to the need for an urgent public health response — one that reduces product potency, prioritizes prevention, limits youth exposure and marketing and treats adolescent cannabis use as a serious health issue, not a benign behavior.”
Cannabis is the most used illicit drug among U.S. adolescents. The Monitoring the Future study shows use rising with grade level — from about 8% in 8th grade to 26% in 12th grade — and according to the 2024 National Survey on Drug Use and Health , more than 10% of all U.S. teens aged 12 to 17 report past-year use. At the same time, average THC levels in California cannabis flower now exceed 20%, far higher than in previous decades, and concentrates can exceed 95% THC.
Unlike many prior studies, the research examined any self-reported past-year cannabis use, with universal screening of teens during standard pediatric care, rather than focusing only on heavy use or cannabis use disorder.
“Even after accounting for prior mental health conditions and other substance use, adolescents who reported cannabis use had a substantially higher risk of developing psychiatric disorders — particularly psychotic and bipolar disorders,” said Kelly Young-Wolff, Ph.D., lead author of the study and senior research scientist at the Kaiser Permanente Division of Research . “This study adds to the growing body of evidence that cannabis use during adolescence could have potentially detrimental, long-term health effects. It’s imperative that parents and their children have accurate, trusted, and evidence-based information about the risks of adolescent cannabis use.”
The study also found that cannabis use was more common among adolescents enrolled in Medicaid and those living in more socioeconomically deprived neighborhoods, raising concerns that expanding cannabis commercialization could exacerbate existing mental health disparities.
The Public Health Institute is an independent nonprofit organization that advances wellbeing and health equity with communities around the world. PHI develops research, leadership and partnerships to build strong public health policy, programs, systems and practices. For more information, visit www.phi.org .
JAMA Health Forum
10.1001/jamahealthforum.2025.6839
Data/statistical analysis
People
Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders
20-Feb-2026
Dr. Young-Wolf reported receiving grants from National Institutes of Health (NIH)/National Institute on Drug Abuse (NIDA) during the conduct of the study. Dr. Silver reported receiving grants from the NIH/NIDA during the conduct of the study. Dr. Pacula reported receiving grants from the NIH/NIDA, and the NIH/National Institute on Alcohol Abuse and Alcoholism (NIAAA) during the conduct of the study; non-financial support from the National Academies of Sciences, Engineering & Medicine, and receiving personal fees from Willkie Farr & Gallagher LLP. Dr. Padon reported receiving grants from NIH/NIDA during the conduct of the study. Dr Campbell reported receiving grants from the NIH/NIDA/NIAAA, the US Federal Drug Administration, and the Opioid Post-Marketing Requirement Consortium during the conduct of the study outside of the submitted work. Dr. Does reported receiving institutional financial support from the Opioid Post-Marketing Requirement Consortium outside the submitted work. No other disclosures were reported.